SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-128468
Filing Date
2023-12-22
Accepted
2023-12-22 06:36:08
Documents
14
Period of Report
2023-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2333444d1_8k.htm   iXBRL 8-K 60180
2 EXHIBIT 2.1 tm2333444d1_ex2-1.htm EX-2.1 722220
3 EXHIBIT 99.1 tm2333444d1_ex99-1.htm EX-99.1 13320
  Complete submission text file 0001104659-23-128468.txt   1149359

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA thrx-20231221.xsd EX-101.SCH 3018
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE thrx-20231221_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE thrx-20231221_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2333444d1_8k_htm.xml XML 3318
Mailing Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142
Business Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142 (857) 400-9491
Theseus Pharmaceuticals, Inc. (Filer) CIK: 0001745020 (see all company filings)

IRS No.: 830712806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40869 | Film No.: 231507127
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)